Aromasin
Aromasin Dragon Pharma — Overview
Aromasin Dragon Pharma contains exemestane at 25 mg per tablet — a steroidal aromatase inhibitor that permanently deactivates the aromatase enzyme rather than competing with it temporarily. This irreversible mechanism, often called suicidal inhibition, is the defining characteristic that separates Aromasin from non-steroidal AIs like Arimidex and Femara, and is the reason it is the preferred AI for PCT and for athletes who have experienced estrogen rebound after stopping other inhibitors mid-cycle.
This Steroid Warehouse page covers the mechanism behind exemestane's irreversible action, how it compares to non-steroidal alternatives, the aromatizing compounds it is used with, and its specific advantages in the post-cycle recovery phase.
About the Compound: Exemestane
Exemestane is a steroidal aromatase inactivator structurally derived from androstenedione. Rather than binding reversibly and competitively to the aromatase enzyme (CYP19A1), it binds covalently and permanently — the enzyme molecule it attaches to is irreversibly deactivated and cannot resume converting androgens to estrogens. New estrogen production only resumes as the body synthesizes fresh aromatase enzyme, a process that takes days rather than hours. This is the foundation of the "suicidal AI" designation.
Because the inhibition is irreversible, estrogen levels remain suppressed even after the last exemestane dose clears the system. There is no pathway for rapid estrogen rebound of the kind that occurs with anastrozole when stopped mid-cycle — a property that makes Aromasin particularly useful at cycle end and throughout the PCT window.
Exemestane's steroidal structure also gives it mild androgenic activity. It does not convert to active androgens meaningfully, but it demonstrates a modest SHBG-lowering effect and is associated with better lipid outcomes than non-steroidal AIs in comparative data — attributed to its partial androgenic rather than purely anti-estrogenic action on lipoprotein metabolism.
What Aromasin Does
Exemestane produces the same primary estrogen management outcomes as other AIs — reduced water retention, lower blood pressure, gynecomastia prevention, and a drier appearance — but its irreversible mechanism and steroidal structure add two practically important properties:
- No rebound estrogen on discontinuation — when exemestane is stopped, aromatase activity resumes gradually as new enzyme is produced; there is no sudden release of previously inhibited enzyme causing E2 to spike, which is a documented risk when stopping anastrozole while aromatizing AAS are still active
- Sustained suppression through dose gaps — the irreversible mechanism means EOD dosing is practical even at moderate testosterone doses; one dose continues suppressing the enzyme molecules it deactivated until they are replaced by new synthesis
- SHBG reduction — exemestane's androgenic structure produces a mild reduction in sex hormone binding globulin, which increases free testosterone fraction; a minor but notable effect absent from non-steroidal AIs
- Lipid-neutral or mildly lipid-favorable profile — in comparative studies, exemestane shows less HDL suppression than anastrozole and letrozole, attributed to its partial androgenic activity partially offsetting the HDL-lowering effect of estrogen reduction
- PCT compatibility — because it suppresses estrogen gradually and without rebound, exemestane can be continued through the early weeks of PCT to prevent estrogenic symptoms as testosterone production slowly resumes, without interfering with the SERM-driven LH/FSH recovery
Dose titration: at 12.5 mg EOD, Aromasin provides meaningful aromatase suppression suitable for moderate testosterone doses (300–400 mg/week). At 25 mg/day, suppression is near-maximal. Most athletes find the effective dose is in between — 12.5–25 mg/day or 25 mg EOD. E2 bloodwork is the only reliable calibration tool regardless of dose.
Who It's For
Aromasin covers the same base use cases as any AI — aromatizing compound users who need estrogen control — but is specifically the preferred choice in three situations:
- Athletes who have experienced estrogen rebound with Arimidex — stopping anastrozole mid-cycle or at cycle end while aromatizing compounds are still active frequently causes a rebound spike; switching to exemestane eliminates this risk
- PCT users who want continued AI coverage — Aromasin can be run alongside Nolvadex or Clomid through the PCT window without the rebound risk that makes stopping a reversible AI at cycle end problematic; it is the standard recommendation for AI use during SERM-based PCT
- Athletes on longer cycles with stable aromatizing compound levels — the irreversible mechanism makes Aromasin well suited for 12–20 week testosterone cycles where consistent estrogen control over many weeks is required without frequent dose adjustment
- Users with lipid sensitivity — when lipid management is already a concern on cycle and the choice is between AIs, exemestane's more favorable HDL profile compared to anastrozole makes it the practical first choice
Context & Related Products
The aromatizing compounds that most commonly require AI support, and how Aromasin compares to the other AI options available:
| Compound / Product | Aromatization Level | Aromasin Role |
|---|---|---|
| Enantat 250 (Test Enanthate) | High | 12.5–25 mg EOD is the typical starting range for a 300–400 mg/week Enanthate cycle. Aromasin's irreversible mechanism is particularly useful here because Enanthate has a long ester — it continues aromatizing for days after the last injection, making rebound-free discontinuation a practical advantage |
| Cypionat 250 (Test Cypionate) | High | Same aromatization profile as Enanthate. Cypionate is frequently run in longer cycles of 16–20 weeks where consistent estrogen control week-over-week matters; Aromasin's stable, progressive suppression suits extended cycles better than a reversible AI that requires uninterrupted daily dosing to maintain its effect |
| Sustanon 270 | High (multi-ester) | Sustanon's mixed esters mean both short and long ester testosterone are active simultaneously. The early E2 spike from Propionate and Phenylpropionate esters makes an on-hand AI mandatory from the start of the cycle; Aromasin's EOD dosing works well with Sustanon's injection frequency |
| Dianabol 20 / Dianabol 50 | Very High | When Dianabol is used as a cycle kickstart for 4–6 weeks, estrogen rises quickly in the first two weeks. Aromasin should be started with the Dianabol; it does not need to be tapered when Dianabol ends because its irreversible suppression will gradually resolve as new aromatase enzyme is produced |
| Deca 300 (Nandrolone Decanoate) | Moderate + progestogenic | Aromasin manages the estrogenic component of Deca. Nandrolone's progestogenic activity is a separate consideration; if prolactin-related symptoms develop, that requires additional management beyond an AI |
When Aromasin is used during PCT, the standard SERM options it pairs with are:
| PCT Product | Role alongside Aromasin |
|---|---|
| Nolvadex | Primary SERM for LH/FSH stimulation. Running Aromasin (12.5 mg EOD) alongside Nolvadex during PCT prevents estrogen from rising as testosterone production resumes — keeping the early recovery window clean without rebound risk |
| Clomid | Dual LH/FSH stimulator. Some athletes run Aromasin + Clomid as a PCT combination, particularly after suppressive injectable cycles; the irreversible AI provides a stable estrogen baseline through the entire recovery window |
For context on how Aromasin compares to the other AIs available:
| AI | Class | Key Difference vs Aromasin |
|---|---|---|
| Arimidex (Anastrozole) | Non-steroidal, reversible | More titratable on a daily basis; rebound estrogen risk if stopped while aromatizing AAS are still active; standard first choice for users who run AI exclusively on-cycle and taper it properly at the end |
| Femara (Letrozole) | Non-steroidal, reversible | Most potent of the three; used when Aromasin or Arimidex is insufficient or when very aggressive estrogen suppression is required; higher over-suppression risk; not recommended for PCT use due to potency and rebound potential |
Side Effects & Management
Aromasin's side effect profile mirrors the AI class broadly: the primary risk is over-suppression of estrogen. Its more favorable lipid profile versus non-steroidal AIs reduces one concern, but the joint and mood effects of low E2 are the same regardless of which AI caused the suppression.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Joint pain and dryness | Over-suppression of estrogen reduces joint lubrication. Exemestane's near-maximal suppression at 25 mg/day makes it easy to push E2 below the functional range — particularly in athletes who are simultaneously running dry compounds like Winstrol or Masteron | Reduce dose to 12.5 mg/day or switch to EOD dosing. Recheck E2. Joint symptoms resolve as estrogen returns to range. Monitor more carefully when Aromasin is stacked with DHT-derived compounds that already reduce water retention |
| HDL reduction (mild vs non-steroidal AIs) | Estrogen supports HDL synthesis; suppressing it pharmacologically still worsens the lipid impact of AAS use, even though exemestane's androgenic structure reduces the magnitude of this effect compared to anastrozole or letrozole | Baseline and mid-cycle lipid panel is standard practice on any AI. Atorvastatin or Rosulip (Rosuvastatin) for HDL support; Ezentia (Ezetimibe) as an add-on for LDL when needed |
| Low libido and mood disruption from over-suppression | Both high and low estrogen produce identical-looking libido and mood symptoms. Distinguishing between them requires an E2 blood test — adjusting exemestane dose without knowing E2 level frequently makes the situation worse | Always confirm E2 before increasing or decreasing dose in response to mood or libido changes. The target functional range for male AAS users is approximately 20–40 pg/mL |
| Mild androgenic effects | Exemestane's steroidal structure carries a small degree of androgenic activity. This is largely a non-issue at standard doses but may be relevant for individuals with sensitivity to androgenic effects (acne, hair) | Not a meaningful concern at 12.5–25 mg/day for the majority of users. Relevant only in combination with multiple androgenic compounds |
References
| Source | Topic | Link |
|---|---|---|
| NCBI Bookshelf / StatPearls | Anabolic steroid use — adverse effects, monitoring, endocrine suppression, hepatic, cardiovascular, and lipid-related risks | NCBI StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Gynecomastia and estrogen-androgen balance — aromatization, estrogen-driven breast tissue effects, diagnosis, and medical management context | Endotext: Gynecomastia ↗ |
| PubMed / PMC | Aromatase inhibitors in men — estrogen reduction, therapeutic use, and safety limitations in male patients | PMC: Aromatase Inhibitors in Men ↗ |
| PubMed | Anabolic-androgenic steroids and lipid changes — HDL suppression, Apo-A1 reduction, and unfavorable lipoprotein effects | PubMed: AAS Effects on Apolipoproteins ↗ |
What is Aromasin?
Aromasin (Exemestane) is an oral aromatase inhibitor for estrogen suppression in steroid cycles; see What is Exemestane. It prevents bloat—consult professionals for safe use.
How often to take Aromasin on cycle?
Take 12.5-25 mg daily or EOD, based on cycle needs; see How to Use. Adjust with bloodwork—consult for personalized dosing.
How fast does Aromasin work?
Aromasin reduces estrogen within 24-48 hours; optimal control in 7-14 days; see Results timeline. Monitor with labs for best results.
How much does Aromasin lower estrogen?
Aromasin lowers estrogen by 85-95%; see Mechanism of Action. Precise control prevents bloat—use bloodwork to avoid over-suppression.
What does Aromasin do for bodybuilders?
Aromasin prevents estrogenic side effects like bloat and gynecomastia; see Key Benefits. It ensures lean gains—monitor with professional guidance.
How quickly does Aromasin start working?
Aromasin begins lowering estrogen activity relatively quickly after use. The full effect depends on hormone levels, dosage strategy, and the compounds stacked with it.
How is Aromasin different from Arimidex?
Aromasin differs from Arimidex in that it permanently binds to the aromatase enzyme, while Arimidex inhibits it temporarily. This makes Aromasin a more irreversible form of estrogen control.
Can Aromasin affect muscle gains?
Aromasin can indirectly influence muscle performance by controlling estrogen levels. Proper balance is important, as extremely low estrogen may negatively impact training performance and recovery.
Related Products
